References


  • Asztalos, B. F. (2004). High-density lipoprotein metabolism and progression of atherosclerosis: new insights from the HDL Atherosclerosis Treatment Study.Current opinion in cardiology, 19(4), 385-391.


  • Bierman, E. L. (1992). George Lyman Duff memorial lecture. Atherogenesis in diabetes. Journal of the American Heart Association(12), 647-656



  • Brock, T. (2008). Inflammation in Atherosclerosis: Oxidants and Oxidized Phospholipids. Cayman Chemical, Atherosclerosis catalog.


  • Catapano, A. L., Maggi, F. M., & Tragni, E. (2000). Low density lipoprotein oxidation, antioxidants, and atherosclerosis. Current opinion in cardiology,15(5), 355.


  • Donetti, E., Soma, M. R., Barberi, L., Paoletti, R., Fumagalli, R., Roma, P., & Catapano, A. L. (1998). Dual effects of the antioxidant agents probucol and carvedilol on proliferative and fatty lesions in hypercholesterolemic rabbits.Atherosclerosis, 141(1), 45-51.



  • Esterbauer, H., Wäg, G., & Puhl, H. (1993). Lipid peroxidation and its role in atherosclerosis. British Medical Bulletin, 49(3), 566-576.

  • Falk, E., De, F., & Shah, P. K. (2009). Ischemic heart disease. London, Manson.

  • FEUERSTEIN, G. Z., & R., R. R. (1995). Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. European Heart Journal.


  • Goldstein, J. L., & Brown, M. S. (1977). The low-density lipoprotein pathway and its relation to atherosclerosis. Annual Review of Biochemistry(46), 897-930.

  • Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., et al. (1989). High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation(79), 8 - 15

  • Gotto, A. M., & Grundy, S. M. (1999). Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial data issues from the interdisciplinary council on reducing the risk for coronary heart disease, ninth council meeting. Circulation(99), E1 - E7.

  • Guibert, R., & Franco, E. D. (1996). Choosing a definition of hypertension: impact on epidemiological estimates. (14, Ed.) Journal of Hypertension, 1275-1280.





  • Kannel, W. B., Hjortland, M. C., & McNamara, P. M. (1976). Menopause and risk of cardiovascular disease. Annals of Internal Medicine(85), 447-452.

  • Lonn, E. (2001). Do Antioxidant Vitamins Protect Against Atherosclerosis? Journal of American College of Cardiology, 1795-1798.

  • MacMahon, S. (1990). Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet(335), 765.

  • McGill, H. C., McMahan, A. C., Zieske, A. W., Malcom, G. T., Tracy, R. E., & Strong, J. P. (2001). Effects of nonlipid risk factors on atherosclerosis in youth with a favorable lipoprotein profile. Circulation(103), 1546-1550.

  • Meydani, M. (2001). Vitamin E and atherosclerosis: beyond prevention of LDL oxidation. The Journal of nutrition, 131(2), 366S-368S.



  • Norata, G., Pirillo, A., & Catapano, A. (2003). Statins and Oxidative Stress During Atherogenesis. European Journal of Cardiovascular Risk.

  • Powell, J. T. (1998). Vascular damage from smoking: disease mechanisms at the arterial wall. Vascular Medicine, 21-28.


  • Rader, D. J., & Daughtery, A. (2008). Translating molecular discoveries into new therapies for atherosclerosis. Nature, international weekly journal of science, 904-913.

  • Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Benjamin, E. J., Berry, J. D., Borden, W. B., et al. (2012). Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Dallas: American Heart Association.




  • Srivastava, R. (2008). Synopsis of Causation: Atherosclerosis. London: United Kingdom Ministry of Defence.

  • Stampfer, M. J. (1991). Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Preventive Medicine(20), 47.


  • Steinberg, D. (1997). Low Density Lipoprotein Oxidation and Its Pathobiological Significance*. Journal of Biological Chemistry, 20963-20966.



  • U.S. Department of Health and Human Services. (1989). Reducing the health consequences of smoking: 25 years of progress. A report of the surgeon general. U.S. Department of Health and Human Services.


  • Wilson, P. W., D'Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998). Prediction of coronary heart disease using risk factor categories. Circulation(97), 1837-1847.

  • Wilson, P. W., Kannel, W. B., Silbershatz, H., & D'Agostino, R. B. (1999). Clustering of metabolic factors and coronary heart disease. Arch Intern Medical(159), 1104-1109.

  • Zhao, X.-Q., Morse, J. S., Dowdy, A. A., Heise, N., DeAngelis, D., Frohlich, J., et al. (2004). Safety and Tolerability of Simvastatin Plus Niacin in Patients with Coronary Artery Disease and Low High-Density Lipoprotein Cholesterol (The HDL Atherosclerosis Treatment Study). The American Journal of Cardiology Vol.93, 307-312.